Arius begins toxicology program for lead anti-cancer antibody in preparation for firs

[Joe]

ARIUS Research Inc., (TSX: ARI) a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.

More... (http://www.news-medical.net/?id=27904)